source
- Novo’s IL-6 inhibitor ziltivekimab may target milder cardio-renal patients after Phase 3 missAt the American Heart Association meeting, investigators discussed new data on Novo Nordisk’s IL-6 inhibitor ziltivekimab, suggesting it could be studied in patients with less severe cardiovascular…
- Rivia unveils AI-driven DataFindings module to accelerate clinical trial data cleaning, Scancell adopts earlySwiss CRO Rivia introduced an AI-powered DataFindings module that integrates with its Rivia Core platform to automate continuous review of clinical trial data. The tool uses AI agents to help user…